🔥 Tophi Formation & Dissolution Simulator

Chronic Hyperuricemia and Silent MSU Crystal Seeding

Urate stays above saturation while crystals seed silently in tissue.

• 6.8 mg/dL: Solubility threshold (plasma MSU saturation limit)
• ~20%: Hyperuricemia prevalence (of US adults)
• 3–42 yr: Time to first tophus (highly variable onset)
• up to 30%: Crystals seen on US (asymptomatic hyperuricemia)

Urate solubility and supersaturation

Serum urate above 6.8 mg/dL exceeds plasma solubility.

Subclinical crystal seeding in joints

Needle-shaped MSU crystals accumulate before any symptoms.

Visible Tophus Nucleation at Joint and Soft Tissue Sites

Crystal aggregates coalesce into a first visible nodule.

• 1st MTP, ear, elbow: Common sites (joint and soft tissue)
• ~5 mm: Median size at detection (palpable nodule)
• Sustained supersaturation: Growth trigger (above 6.8 mg/dL)
• ~12%: Palpable tophi at 10 yr (of untreated gout)

Nucleation core and fibrous capsule

A dense crystal core forms a fibrovascular capsule.

Chronic inflammatory rim formation

Macrophages and giant cells wall off the deposit.

Tophus Growth Under Continued Hyperuricemia

Continued high urate drives steady chalky-mass expansion.

• ~1–5 mm/yr: Growth rate (untreated) (diameter increase)
• Elevated: Bone erosion risk (periarticular joint damage)
• Rises with size: Flare frequency (acute inflammatory episodes)
• Often irreversible: Structural damage (without urate control)

Layered crystal accretion mechanics

New crystal layers deposit fastest at the surface.

Periarticular bone erosion

Expanding mass compresses and erodes adjacent bone.

Sustained Urate-Lowering Therapy Initiated

Sustained therapy pushes serum urate below saturation.

• <5 mg/dL: Target urate (tophaceous) (below solubility margin)
• Allopurinol, febuxostat: First-line agents (xanthine oxidase inhibitors)
• Transient rise: Early flare risk (crystal mobilization phase)
• ~4–8 wk: Time to urate plateau (with dose titration)

Xanthine oxidase inhibition mechanism

Lower urate production shifts the crystal equilibrium.

Flare prophylaxis during initiation

Low-dose colchicine covers the early mobilization period.

Progressive Tophus Shrinkage and Dissolution

Macrophages resorb the tophus over months to years.

• Months to years: Dissolution timescale (depends on undersaturation)
• ~50% by 5 yr: Full resolution reported (with sustained low urate)
• Depth below 6.8 mg/dL: Key driver (undersaturation magnitude)
• Ultrasound / DECT: Monitoring tool (serial volume tracking)

Crystal dissolution kinetics

Undersaturated plasma slowly redissolves surface crystals first.

Macrophage-mediated clearance

Giant cells phagocytose and clear liberated crystal debris.